MX2011007989A - Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b. - Google Patents

Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b.

Info

Publication number
MX2011007989A
MX2011007989A MX2011007989A MX2011007989A MX2011007989A MX 2011007989 A MX2011007989 A MX 2011007989A MX 2011007989 A MX2011007989 A MX 2011007989A MX 2011007989 A MX2011007989 A MX 2011007989A MX 2011007989 A MX2011007989 A MX 2011007989A
Authority
MX
Mexico
Prior art keywords
aurora kinase
markers
predict
inhibitor therapy
monitor response
Prior art date
Application number
MX2011007989A
Other languages
English (en)
Inventor
Mark Anderson
Dimitri Semizarov
Jameel Shah
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011007989A publication Critical patent/MX2011007989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a identificar la presencia o ausencia de una o más ganancias de número de copia en el gen ABCB1, el gen ABCB4 o combinaciones de los mismos, identificar pacientes elegibles para recibir terapia con un inhibidor de Aurora cinasa, ya sea como monoterapia o como parte de una terapia de combinación, y verificar la respuesta del paciente a dicha terapia.
MX2011007989A 2009-01-31 2010-01-29 Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b. MX2011007989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14895709P 2009-01-31 2009-01-31
PCT/US2010/022518 WO2010088470A1 (en) 2009-01-31 2010-01-29 Markers to predict and monitor response to aurora kinase b inhibitor therapy

Publications (1)

Publication Number Publication Date
MX2011007989A true MX2011007989A (es) 2011-08-17

Family

ID=42101875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007989A MX2011007989A (es) 2009-01-31 2010-01-29 Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b.

Country Status (7)

Country Link
US (1) US20100196907A1 (es)
EP (2) EP2479288A1 (es)
JP (1) JP5616905B2 (es)
CN (1) CN102365372B (es)
CA (1) CA2749945A1 (es)
MX (1) MX2011007989A (es)
WO (1) WO2010088470A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532006T3 (es) * 2009-11-20 2015-03-23 Pharnext Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth
EP2699696B1 (en) * 2011-04-18 2018-06-13 Cornell University Molecular subtyping, prognosis and treatment of prostate cancer
EP2602330A1 (en) * 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
BR112016004922B1 (pt) * 2013-09-16 2022-08-23 Astrazeneca Ab Nanopartículas poliméricas terapêuticas e composição farmacêutica compreendendo as mesmas
EP3877056A4 (en) * 2018-11-09 2022-08-17 The Broad Institute, Inc. TEPOXALINE TARGETS OF ABCB1 OVEREXPRESSING CANCERS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) * 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
US5464746A (en) * 1991-12-17 1995-11-07 Abbott Laboratories Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
US5424414A (en) 1991-12-17 1995-06-13 Abbott Laboratories Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
US7419821B2 (en) * 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) * 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) * 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
WO2006123246A2 (en) * 2005-02-11 2006-11-23 Aurelium Biopharma Inc. Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors
JP5391279B2 (ja) 2008-10-31 2014-01-15 アッヴィ・インコーポレイテッド １種以上の医薬組成物の有効性を試験することに使用する癌細胞系のパネルを構築するための方法
JP6812855B2 (ja) 2017-03-10 2021-01-13 Jnc株式会社 ジアルキルアミノシランの製造方法

Also Published As

Publication number Publication date
CA2749945A1 (en) 2010-08-05
EP2391734B1 (en) 2013-06-05
EP2391734A1 (en) 2011-12-07
JP2012516160A (ja) 2012-07-19
US20100196907A1 (en) 2010-08-05
CN102365372B (zh) 2016-05-25
WO2010088470A1 (en) 2010-08-05
JP5616905B2 (ja) 2014-10-29
EP2479288A1 (en) 2012-07-25
CN102365372A (zh) 2012-02-29

Similar Documents

Publication Publication Date Title
MY172372A (en) Compositions and methods for lowering triglycerides
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2012003612A (es) Bifidobacterium longum atcc baa-99 (bl999) y control de peso.
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MX339584B (es) Inhibidores de pi3 cinasa y usos de los mismos.
GB2453058A (en) Kinase antagonists
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
MY161495A (en) Virus like particle compositions and methods of use
IN2012DN02469A (es)
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
UA107089C2 (xx) Штами lactobacillus plantarum як гіпохолестеринемічні агенти
MX356779B (es) Composicion que comprende un agente de control biologico y un fungicida.
TNSN08400A1 (en) Organic compounds and their uses
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
IN2012DN02471A (es)
MX349048B (es) Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2011007989A (es) Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b.
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration